secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0000950170-23-049919
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto explores strategic alternatives; cuts workforce 70%, CMO out
--------------------------------------------------------------------

- Workforce reduction of ~29 employees (~70% of headcount) approved Sept 20, 2023.
- Estimated restructuring charges of ~$2.8M mostly in Q3 2023; execution substantially complete by Q4 2023.
- CMO Bertil Lindmark's position eliminated effective Oct 1, 2023; CEO Hans Schambye assumes duties.
- CEO and CFO retention bonuses: CEO up to DKK 2,090,208 for milestones; CFO $183,456 target bonus.
- Cash and equivalents $52.1M as of June 30, 2023; no timetable for strategic review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023049919/0000950170-23-049919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000095017023049919/glto-20230920.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer